Most of us want to avoid getting mosquito bites because they’re itchy and uncomfortable, but they can also pass along serious illnesses.
A team of scientists at the University of Pittsburgh, Washington University School of Medicine in St. Louis and Massachusetts General Hospital is using a $14.5 million grant from the Department of Defense to create a technology to prevent infection from three viruses carried by mosquitoes.
One of those viruses, Eastern equine encephalitis, or EEE, is rare but very dangerous – The Centers for Disease Control and Prevention says it’s fatal for about 30 percent of those infected, and many others suffer lasting damage. A 2020 paper by the Pitt researchers and others put the mortality range even higher — at 30% to 70%.
It can also cause fever, chills, nausea, vomiting, meningitis and brain inflammation. Mosquitoes that carry EEE are typically found along the East Coast, but public health experts have also found cases in Michigan and in southern states like Missouri, Arkansas and Louisiana.
According to the CDC, 110 cases of EEE have been reported from 2011 to 2020. Only one was reported in Pennsylvania during those years, in 2018.
Those who do recover from EEE typically suffer lasting neurological damage. And as climate change accelerates, bringing about heat waves and species fluctuation, virologists expect EEE and other mosquito-borne viruses to reach states where they are not typically found.
Read More
“Prior to the 2019 outbreak, I don’t think there had been any inkling that the virus might be found in Michigan,” says Douglas Reed, an associate professor in the department of immunology at Pitt who is one of the lead scientists on the study.
He and William Klimstra, a member of the Center for Vaccine research and an associate professor in the department of immunology, are working with colleagues to develop a therapeutic aimed to prevent infection from these viruses. Working with Michael Diamond at Washington University, they first used CRISPR-CAS9 technology — a tool scientists use to locate and cut out certain gene sequences — to identify which proteins were needed for another mosquito-borne virus, Venezuelan equine encephalitis, to make copies of itself. They then synthesized a “decoy” protein that blocked the virus from entering the cell. This decoy protein also made it harder for the virus to replicate, preventing later infection.
The technology was developed and used in the Diamond laboratory and then confirmed in the Klimstra laboratory at Pitt.
The team’s plan is to develop a therapeutic that could work on three viruses: Eastern equine encephalitis, Venezuelan equine encephalitis virus, and Western equine encephalitis. It could be especially useful for soldiers heading into a war zone where infected mosquitoes might be used as a weapon, the researchers said.
Mr. Klimstra, overall principal investigator on the research, also thinks this technology could be applied to other virus families. “What’s happening right now is that people have recognized that this is a really effective way of doing this,” he said. “We’re in a sort of a renaissance period in terms of identifying these host cell structures.”
Mosquitoes that carry EEE pick it up by feeding on birds. The mosquito can then spread the virus to other animals, like horses or humans. Nine out of 10 horses that get infected die from the virus; humans are luckier and don’t get bitten by infected mosquitoes as often. But the Department of Defense is wary of these kinds of viruses being weaponized by state or individual actors because they have been in the past.
In 1925, the Geneva Protocol was created to ban the use of biological and chemical agents in international conflict. But the US didn’t sign it, and in 1941, it created a biological warfare research program, fearing that other countries were doing the same. Venezuelan equine encephalitis virus was one of the agents standardized for use by the Army Chemical Corps, according to a 2002 article published in International Security by Jonathan B. Tucker, a biological and chemical weapons expert and writer.
Over the years, many tests on biological and chemical weapons were conducted, and in one case, some 3,000 sheep died when particles of a nerve agent called VX drifted past the test site. The Army paid damages to the farmer, according to Mr. Tucker’s article. This event, along with the use of Agent Orange and tear gas during the Vietnam war years, turned public perception of biological and chemical warfare sour.
The conditions laid out in the Geneva Protocol were later updated in a new treaty called the Biological Weapons Convention, which the US ratified in 1975. Today, given the severity of EEE, the Department of Defense wants to create a therapeutic to have on hand. “To protect the soldiers who might go into harm’s way, [the DOD] needs licensed drugs and vaccines that can protect against this aerosol threat,” Mr. Reed said.
The technology the Pitt and Washington University researchers are developing is not a vaccine. A vaccine stimulates an immune response in the host, which is what fights off the virus.
“What we’re doing is putting a molecule in that directly engages the virus and blocks its ability to replicate and cause disease,” Mr. Klimstra said. He thinks that if EEE infections were to increase in the human population, people would welcome the technology because of how severe the virus is.
With this project, Mr. Klimstra has transitioned from abstract research to a more translational approach. Identifying the relevant structures and conducting animal studies means seeing results can take years, so he says he’s enjoyed getting to see his research advance toward clinical trial. Mr. Klimstra hopes that by the end of the five-year grant, their team will be ready to begin phase I of testing their therapeutic in a human population. Until then, they’re working hard to perfect the technology and learn more about these deadly viruses.
Correction: An earlier version of this article listed the incorrect academic affiliation at the University of Pittsburgh for William Klimstra. He is a member of the Center for Vaccine Research and an associate professor in the department of immunology.







Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.